资金流向方面，深港通医疗（983035）指数成份股当日主力资金净流出合计1.41亿元，游资资金净流出 合计1086.24万元，散户资金净流入合计1.52亿元。成份股资金流向详情见下表： 深港通医疗（983035）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月16日，深港通医疗（983035）指数报收于4340.85点，跌0.58%，成交71.81亿元， 换手率0.81%。当日该指数成份股中，上涨的有17家，福瑞股份以4.6%的涨幅领涨，下跌的有41家，健 康之路以5.81%的跌幅领跌。 ...

证券之星消息，12月16日，深港通医疗(港币)（983036）指数报收于4264.99点，跌0.54%，成交79.31亿 元，换手率0.81%。当日该指数成份股中，上涨的有17家，福瑞股份以4.6%的涨幅领涨，下跌的有41 家，健康之路以5.81%的跌幅领跌。 深港通医疗(港币)（983036）指数十大成份股详情如下： | 深港通医疗(港币)指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | hk02587 | 健康之路 | | 3.97 | -5.81% | 34.85 | 计算机 | | hk02522 | 一脉阳光 | i | 8.23 | -4.93% | 32.59 | 医药生物 | | hk06086 | 方丹健客 | | 2.48 | -4.55% | 33.20 | 医药生物 | | sz301584 | 建发致新 | -- | 31.07 | -3.87% | 130.89 | 医药生物 | | hk02609 | ...

Group 1 - The core viewpoint of the news is that Kangtong Medical has shown a decrease in financing activities and a significant drop in revenue and net profit for the year 2025 [1][2] - As of December 15, Kangtong Medical's financing balance is 28.75 million yuan, accounting for 2.07% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] - The company reported a revenue of 344 million yuan for the period from January to September 2025, representing a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% year-on-year [2] Group 2 - Kangtong Medical's main business includes providing medical gas systems and clean operating room solutions, with revenue composition being 55.69% from clean equipment and systems, 37.30% from medical gas equipment, and 4.06% from other medical device sales [1] - As of December 10, the number of shareholders for Kangtong Medical is 7,355, a decrease of 1.68% from the previous period, while the average circulating shares per person increased by 1.71% to 8,571 shares [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]

【深圳商报讯】(记者陈燕青)港通医疗（301515）近日宣布聘任夏沧澜为副总经理。最近两年，港通医 疗业绩持续走弱，去年净利润大降逾八成，今年前三季度又出现亏损。由于业绩不佳，公司高管薪酬总 额明显下滑。 根据2024年年报数据，港通医疗董事及高级管理人员(剔除独立董事等)的薪酬总额为339.1万元，人均年 薪约35.26万元。其中，公司董事长兼总经理陈永薪酬最高，为62.72万元；副总经理刘洪兵薪酬最低， 为22.83万元。 值得一提的是，最近几年港通医疗高管薪酬持续下滑。数据显示，公司高管薪酬总额从2022年的564.58 万元降至2024年的339.1万元，降幅近四成，薪酬大降或与业绩不佳有关。 资料显示，港通医疗2023年7月上市，主营业务为医用气体装备及系统、医用洁净装备及系统的研发、 设计、制造、集成及运维服务。 财务数据显示，今年前三季度港通医疗实现营业收入3.44亿元，同比大幅减少30.06%；归母净利润 为-1020.84万元，同比由盈转亏。2023年公司净利润8310万元，同比增长12.4%；2024年公司实现净利 润1442万元，同比下降82.6%。 港通医疗7月曾发布股权激励计划。该激 ...

12月12日，港通医疗发布公告，聘任夏沧澜先生为公司副总经理。 资料显示，夏沧澜先生，中国国籍，无境外永久居留权，1981年出生，博士研究生学历，正高级经济 师。曾任上海宏联工贸有限公司加贝分公司销售代表；中达电通股份有限公司产品维修工程师、技术支 持工程师、成都产品维修处经理；菲律宾SCJohnson客服代表、储备经理；成都华气厚普机电设备股份 有限公司总经理助理、人力资源总监、LNG成套设备中心副总经理、副总经理、董事；青岛诺安机电 科技有限公司总经理；成都海科机械设备制造有限公司总经理；中际联合(北京)科技股份有限公司供应 链管理中心总经理；深圳市万德数字科技有限公司总经理。 四川港通医疗设备集团股份有限公司（股票代码：301515）是一家现代化的医疗器械研发制造及智慧医 疗专业系统整体方案提供商，致力于解决医用气体供应及医疗感染问题，为各类医疗机构提供安全、稳 定、高效、智能的生命支持系统和生命支持区域，主营业务为医用气体装备及系统、医用洁净装备及系 统的研发、设计、制造、集成及运维服务。2023年7月25日，港通医疗在深交所创业板成功挂牌。 近三年董事和高级管理人员薪酬方面，港通医疗2022年高管薪 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

截至2025年12月12日收盘，港通医疗（301515）报收于19.84元，较前一交易日下跌2.02%，最新总市值 为19.84亿元。该股当日开盘20.26元，最高20.48元，最低18.0元，成交额达3525.03万元，换手率为 2.68%。 同日，港通医疗发布公告称，公司于2025年12月12日召开第五届董事会第七次会议，审议通过聘任夏沧 澜先生为公司副总经理的议案。公告显示，夏沧澜先生具备相关法律法规和公司章程规定的任职资格， 未持有公司股份，与公司实际控制人、其他董事、高级管理人员及持股5%以上股东无关联关系。其任 期自董事会审议通过之日起至第五届董事会任期届满为止。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《关于聘任公司副总经理的公告》 《第五届董事会第七次会议决议公告》 ...

证券日报网讯 12月12日晚间，港通医疗发布公告称，公司第五届董事会第七次会议于2025年12月12日 召开，审议通过了《关于聘任公司副总经理的议案》，同意聘任夏沧澜先生为公司副总经理，任期自第 五届董事会第七次会议审议通过之日起至第五届董事会任期届满之日止。 （文章来源：证券日报） ...

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4302.26 points, up 1.09% with a trading volume of 10.694 billion HKD and a turnover rate of 1.0% [1] - Among the constituent stocks, 39 stocks rose, with Baize Medical leading with a 5.14% increase, while 16 stocks fell, with Furuide leading the decline at 3.23% [1] Fund Flow Analysis - The total net inflow of main funds into the Shenzhen-Hong Kong Stock Connect Medical Index constituents was 80.9503 million HKD, while speculative funds saw a net outflow of 283 million HKD, and retail investors had a net inflow of 202 million HKD [2]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4383.23 points, up 0.98% with a trading volume of 9.693 billion yuan and a turnover rate of 1.0% [1] - Among the constituent stocks, 39 stocks rose, with Baize Medical leading with a 5.14% increase, while 16 stocks fell, with Furuide leading the decline at 3.23% [1] - The net inflow of main funds into the Shenzhen-Hong Kong Medical Index constituents totaled 80.9503 million yuan, while speculative funds saw a net outflow of 283 million yuan, and retail investors had a net inflow of 202 million yuan [2] Group 1 - The Shenzhen-Hong Kong Medical Index reported a positive performance with a 0.98% increase [1] - Baize Medical showed the highest gain among constituents with a 5.14% rise [1] - Furuide experienced the largest decline with a 3.23% drop [1] Group 2 - The total net inflow of main funds was 80.9503 million yuan [2] - Speculative funds experienced a significant net outflow of 283 million yuan [2] - Retail investors contributed to a net inflow of 202 million yuan [2]